Division of Neurointerventional Radiology, Neuroscience Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.
Division of Vascular Neurology, Neuroscience Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.
J Neurointerv Surg. 2019 Feb;11(2):141-146. doi: 10.1136/neurintsurg-2018-013957. Epub 2018 Jul 3.
To report the efficacy of A Direct Aspiration first-Pass Thrombectomy (ADAPT) technique with larger-bore ACE aspiration catheters as first-line treatment for anterior circulation emergent large vessel occlusions (ELVOs), and assess for the presence of a first-pass effect with ADAPT.
We retrospectively reviewed 152 consecutive patients with anterior circulation ELVOs treated with the ADAPT technique as first-line treatment using ACE60, 64, or 68 at our institution. Baseline characteristics, procedural variables, and modified Rankin Scale (mRS) at 90 days were recorded.
Fifty-seven patients were treated with ACE60 (37.5%), 35 with ACE64 (23%), and 60 with ACE68 (39.5%). Median groin puncture to reperfusion time was 30 min with ACE60, 26 min with ACE64, and 19.5 min with ACE68. Successful reperfusion after the first ADAPT pass was 33% with ACE60 and 53% with ACE68 (P=0.04). The stent-retriever rescue rate was 26% with ACE60, 3% with ACE64, and 10% with ACE68 (P=0.004). In multivariate logistic regression analysis, use of the ACE68 aspiration catheter was an independent predictor of successful reperfusion after the first ADAPT pass (P=0.016, OR1.67, 95% CI 1.1 to 2.54), and successful reperfusion after the first ADAPT pass was an independent predictor of good clinical outcome at 90 days (P=0.0004, OR6.2, 95% CI 2.27 to 16.8).
Use of the larger-bore ACE 68 aspiration catheter was associated with shorter groin puncture to reperfusion time, higher rate of successful reperfusion after the first ADAPT pass, and lower rate of stent-retriever rescue. Further, a first-pass effect was demonstrated in our ADAPT patient cohort.
报告使用较大口径 ACE 抽吸导管的直接抽吸首次通过血栓切除术(ADAPT)技术作为治疗前循环紧急大血管闭塞(ELVO)的一线治疗方法的疗效,并评估 ADAPT 中的首次通过效应。
我们回顾性分析了在我院接受 ADAPT 技术治疗的 152 例前循环 ELVO 患者,使用 ACE60、64 或 68 抽吸导管作为一线治疗。记录基线特征、操作变量和 90 天改良 Rankin 量表(mRS)。
57 例患者接受 ACE60(37.5%)治疗,35 例患者接受 ACE64(23%)治疗,60 例患者接受 ACE68(39.5%)治疗。ACE60 的股动脉穿刺至再通时间中位数为 30 分钟,ACE64 为 26 分钟,ACE68 为 19.5 分钟。首次 ADAPT 通过后成功再通率 ACE60 为 33%,ACE68 为 53%(P=0.04)。支架取栓挽救率 ACE60 为 26%,ACE64 为 3%,ACE68 为 10%(P=0.004)。多变量逻辑回归分析显示,使用 ACE68 抽吸导管是首次 ADAPT 通过后成功再通的独立预测因素(P=0.016,OR1.67,95%CI 1.1 至 2.54),首次 ADAPT 通过后成功再通是 90 天良好临床结果的独立预测因素(P=0.0004,OR6.2,95%CI 2.27 至 16.8)。
使用较大口径 ACE 68 抽吸导管与股动脉穿刺至再通时间更短、首次 ADAPT 通过后再通率更高、支架取栓挽救率更低相关。此外,我们的 ADAPT 患者队列中存在首次通过效应。